Robert J. Weiland
Keine laufenden Positionen mehr
Profil
Robert J.
Weiland served as Vice President-Strategy at Baxter International, Inc. from 2009 to 2016.
He was also Vice President & General Manager at The Medicines Co. from 2004 to 2006.
Weiland served as VP-Operations & Strategic Analytics at Takeda Pharmaceuticals U.S.A., Inc. from 2005 to 2008.
He was an Independent Director at CymaBay Therapeutics, Inc. from 2016 to 2020.
Weiland's education includes an undergraduate degree from DeSales University and an MBA from The Wharton School of the University of Pennsylvania.
Ehemalige bekannte Positionen von Robert J. Weiland
| Unternehmen | Position | Ende |
|---|---|---|
| CYMABAY THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 24.01.2020 |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | 01.01.2016 |
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | 01.05.2008 |
| THE MEDICINES COMPANY | Corporate Officer/Principal | 01.01.2006 |
| PACIRA BIOSCIENCES, INC. | Corporate Officer/Principal | - |
Ausbildung von Robert J. Weiland
| DeSales University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PACIRA BIOSCIENCES, INC. | Health Technology |
| BAXTER INTERNATIONAL INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
